F
Ferdynand J. Kos
Researcher at City of Hope National Medical Center
Publications - 3
Citations - 70
Ferdynand J. Kos is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Pembrolizumab & Modified vaccinia Ankara. The author has an hindex of 3, co-authored 3 publications receiving 44 citations.
Papers
More filters
Journal ArticleDOI
Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.
Vincent Chung,Ferdynand J. Kos,Nicola Hardwick,Yuan Yuan,Joseph Chao,Daneng Li,James Waisman,M Li,Kathryn Zurcher,Paul Frankel,Don J. Diamond +10 more
TL;DR: The combination of p53MVA vaccine with pembrolizumab is feasible, safe, and may offer clinical benefit in select group of patients that should be identified through further studies.
Journal ArticleDOI
Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab
Yuan Yuan,Ferdynand J. Kos,Ting-Fang He,Hongwei H. Yin,M Li,Nicola Hardwick,Kathryn Zurcher,Daniel Schmolze,Peter P. Lee,Raju Pillai,Vincent Chung,Don J. Diamond +11 more
TL;DR: Activation of p53-specific T cell responses and elevation of multiple immune response genes in peripheral blood correlated with the rapid clinical response which lasted for 6 months after the initiation of combined therapy.
Journal ArticleDOI
A phase 1 study of p53MVA vaccine in combination with pembrolizumab.
Vincent Chung,Ferdynand J. Kos,Nicola Hardwick,Yuan Yuan,Joseph Chao,M Li,Kathryn Zurcher,Paul Frankel,Daneng Li,James Waisman,Don J. Diamond +10 more
TL;DR: This phase 1 study evaluates the safety and tolerability of the p53MVA vaccine in combination with pembrolizumab and observed robust p53-specific CD8+ T cell responses which were further enhanced by anti-PD-1 treatment.